Drug Trial Radar · NCT05552469
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Actual
Start
May 8, 2023
Primary completion
Feb 1, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic myelomonocytic leukemia (LR CMML) and High-Risk Clonal Cytopenia of Undetermined Significance (HR CCUS).
Conditions
- Myeloid Diseases
Interventions
DFV890Drug
DFV890 Single Agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-limiting Toxicities (DLTs)Time frame: 28 days
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 36 months
- Incidence of dose interruptions, discontinuations and reductionsTime frame: 36 months
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
Stanford Cancer Center
Stanford, California
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Northwestern University
Chicago, Illinois
Sidney Kimmel CCC At JH
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Weill Cornell Medicine NY-Presb
New York, New York
Memorial Sloan Kettering Cancer Ctr
New York, New York
Vanderbilt University Medical Ctr
Nashville, Tennessee
Univ of TX MD Anderson Cancer Cntr
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Cardiff, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.